

# Maiken Cavling Arendrup

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4668131/publications.pdf>

Version: 2024-02-01

157  
papers

10,869  
citations

41323

49  
h-index

33869

99  
g-index

158  
all docs

158  
docs citations

158  
times ranked

8728  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Emerging Terbinafine-Resistant <i>Trichophyton</i> Epidemic: What Is the Role of Antifungal Susceptibility Testing?. <i>Dermatology</i> , 2022, 238, 60-79.	0.9	36
2	Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient: Mind the diagnostic gap. <i>Journal De Mycologie Medicale</i> , 2022, 32, 101228.	0.7	8
3	Comment on: Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1209-1210.	1.3	6
4	A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 141.	1.5	6
5	Increasing Terbinafine Resistance in Danish <i>Trichophyton</i> Isolates 2019–2020. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 141.	1.5	36
6	Azole resistance in <i>Aspergillus fumigatus</i> . The first 20-year's Data from the Danish National Surveillance Study, 2018–2020. <i>Mycoses</i> , 2022, 65, 419-428.	1.8	17
7	OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	1.3	1
8	Candidemia among Hospitalized Pediatric Patients Caused by Several Clonal Lineages of <i>Candida parapsilosis</i> . <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 183.	1.5	6
9	Early phenotypic detection of fluconazole- and anidulafungin-resistant <i>Candida glabrata</i> isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1655-1661.	1.3	2
10	Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2053-2073.	1.3	27
11	Disinfection trials with terbinafine-susceptible and terbinafine-resistant dermatophytes. <i>Mycoses</i> , 2022, 65, 741-746.	1.8	5
12	Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 795-812.	1.9	23
13	Invasive aspergillosis in patients with severe COVID-19 pneumonia. <i>Clinical Microbiology and Infection</i> , 2021, 27, 147-148.	2.8	51
14	How to: perform antifungal susceptibility testing of microconidia-forming dermatophytes following the new reference EUCAST method E.Def 11.0, exemplified by <i>Trichophyton</i> . <i>Clinical Microbiology and Infection</i> , 2021, 27, 55-60.	2.8	51
15	In-vitro pharmacokinetic/pharmacodynamic model data suggest a potential role of new formulations of posaconazole against <i>Candida krusei</i> but not <i>Candida glabrata</i> infections. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106291.	1.1	6
16	Dissection of the Activity of Agricultural Fungicides against Clinical <i>Aspergillus</i> Isolates with and without Environmentally and Medically Induced Azole Resistance. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 141.	1.0	10
17	ISO standard 20776-1 or serial 2-fold dilution for antifungal susceptibility plate preparation: that is the question!. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1793-1799.	1.3	6
18	Comparative Pharmacodynamics of Echinocandins against <i>Aspergillus fumigatus</i> Using an In Vitro Pharmacokinetic/Pharmacodynamic Model That Correlates with Clinical Response to Caspofungin Therapy: Is There a Place for Dose Optimization?. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	6

#	ARTICLE	IF	CITATIONS
19	The Role of New Posaconazole Formulations in the Treatment of <i>Candida albicans</i> Infections: Data from an <i>In Vitro</i> Pharmacokinetic-Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	6
20	Photodynamic therapy: A treatment option for terbinafine resistant <i>Trichophyton</i> species. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 33, 102169.	1.3	5
21	Update 2016–2018 of the Nationwide Danish Fungaemia Surveillance Study: Epidemiologic Changes in a 15-Year Perspective. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 491.	1.5	15
22	<i>Aspergillus flavus</i> Infections in Children With Leukemia Despite Liposomal Amphotericin-B Prophylaxis. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 749-752.	1.1	2
23	Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent <i>Candida</i> spp. to Triazoles and Amphotericin B and <i>Aspergillus</i> spp. to Caspofungin: Further Assessment of Modal Variability. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0109321.	1.4	12
24	Lack of relationship between genotype and virulence in <i>Candida</i> species. <i>Revista Iberoamericana De Micologia</i> , 2021, 38, 9-11.	0.4	0
25	Intensive Care Antifungal Stewardship Programme Based on T2 <i>Candida</i> PCR and <i>Candida</i> Mannan Antigen: A Prospective Study. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 1044.	1.5	2
26	Olorofim Susceptibility Testing of 1,423 Danish Mold Isolates Obtained in 2018-2019 Confirms Uniform and Broad-Spectrum Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	20
27	Manogepix (APX001A) <i>In Vitro</i> Activity against <i>Candida auris</i> : Head-to-Head Comparison of EUCAST and CLSI MICs. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	30
28	Introduction of a Comprehensive Diagnostic and Interdisciplinary Management Approach in Haematological Patients with Mucormycosis: A Pre and Post-Intervention Analysis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 268.	1.5	9
29	The one health problem of azole resistance in <i>Aspergillus fumigatus</i> : current insights and future research agenda. <i>Fungal Biology Reviews</i> , 2020, 34, 202-214.	1.9	68
30	Azole-Resistant <i>Aspergillus fumigatus</i> Among Danish Cystic Fibrosis Patients: Increasing Prevalence and Dominance of TR34/L98H. <i>Frontiers in Microbiology</i> , 2020, 11, 1850.	1.5	22
31	Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of <i>Candida auris</i> Infections. <i>Antibiotics</i> , 2020, 9, 539.	1.5	38
32	Rezafungin <i>In Vitro</i> Activity against Contemporary Nordic Clinical <i>Candida</i> Isolates and <i>Candida auris</i> Determined by the EUCAST Reference Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	34
33	Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for <i>Candida albicans</i> Using a Validated <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	4
34	Manogepix (APX001A) Displays Potent <i>In Vitro</i> Activity against Human Pathogenic Yeast, but with an Unexpected Correlation to Fluconazole MICs. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	19
35	Genotyping Reveals High Clonal Diversity and Widespread Genotypes of <i>Candida</i> Causing Candidemia at Distant Geographical Areas. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 166.	1.8	20
36	<i>In Vitro</i> Activity of Ibrexafungerp (SCY-078) against <i>Candida auris</i> Isolates as Determined by EUCAST Methodology and Comparison with Activity against <i>C. albicans</i> and <i>C. glabrata</i> and with the Activities of Six Comparator Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	50

#	ARTICLE	IF	CITATIONS
37	<i>In Vitro</i> Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC Determination. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	17
38	Revision of EUCAST breakpoints: consequences for susceptibility of contemporary Danish mould isolates to isavuconazole and comparators. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2573-2581.	1.3	3
39	Candidemia <i>Candida albicans</i> clusters have higher tendency to form biofilms than singleton genotypes. <i>Medical Mycology</i> , 2020, 58, 887-895.	0.3	2
40	Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWP and EBMT, EORTC and DG and SEIFEM survey. <i>Mycoses</i> , 2020, 63, 420-429.	1.8	7
41	A multicentre study to optimize echinocandin susceptibility testing of <i>Aspergillus</i> species with the EUCAST methodology and a broth microdilution colorimetric method. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1799-1806.	1.3	10
42	Photodynamic therapy treatment of superficial fungal infections: A systematic review. <i>Photodiagnosis and Photodynamic Therapy</i> , 2020, 31, 101774.	1.3	66
43	Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1807-1819.	1.3	37
44	Isavuconazole in a Successful Combination Treatment of Disseminated Mucormycosis in a Child with Acute Lymphoblastic Leukaemia and Generalized Haemochromatosis: A Case Report and Review of the Literature. <i>Mycopathologia</i> , 2019, 184, 81-88.	1.3	25
45	Emerging Terbinafine Resistance in <i>Trichophyton</i> : Clinical Characteristics, Squalene Epoxidase Gene Mutations, and a Reliable EUCAST Method for Detection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	109
46	EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	11
47	Development and multicentre validation of an agar-based screening method for echinocandin susceptibility testing of <i>Aspergillus</i> species. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2247-2254.	1.3	8
48	ECMM <i>Candida</i> Reg A ready to use platform for outbreaks and epidemiological studies. <i>Mycoses</i> , 2019, 62, 920-927.	1.8	19
49	Voriconazole efficacy against <i>Candida glabrata</i> and <i>Candida krusei</i> : preclinical data using a validated in vitro pharmacokinetic/pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 75, 140-148.	1.3	4
50	The fading boundaries between patient and environmental routes of triazole resistance selection in <i>Aspergillus fumigatus</i> . <i>PLoS Pathogens</i> , 2019, 15, e1007858.	2.1	41
51	Species distribution and antifungal susceptibility profile of <i>Candida</i> isolates from blood and other normally sterile foci from pediatric ICU patients in Tehran, Iran. <i>Medical Mycology</i> , 2019, 58, 201-206.	0.3	11
52	Diagnostic Performance of <i>Candida</i> Among ICU Patients With Risk Factors for Invasive Candidiasis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz136.	0.4	36
53	Would you like to purchase a rodent with dermatophytes?. <i>Mycoses</i> , 2019, 62, 584-587.	1.8	10
54	EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	30

#	ARTICLE	IF	CITATIONS
55	Relevance of heterokaryosis for adaptation and azole-resistance development in <i>Aspergillus fumigatus</i> . Proceedings of the Royal Society B: Biological Sciences, 2019, 286, 20182886.	1.2	15
56	In Vivo Selection of a Unique Tandem Repeat Mediated Azole Resistance Mechanism (TR <sub>120</sub> ) in <i>Aspergillus fumigatus</i> cyp51A, Denmark. Emerging Infectious Diseases, 2019, 25, 577-580.	2.0	49
57	Pediatric Candidemia Epidemiology and Morbidities. Pediatric Infectious Disease Journal, 2019, 38, 464-469.	1.1	26
58	Diagnostic accuracy of the 1,3-β-D-glucan test for pneumocystis pneumonia in a tertiary university hospital in Denmark: A retrospective study. Medical Mycology, 2019, 57, 710-717.	0.3	13
59	Recurrent terbinafine resistant <i>Trichophyton rubrum</i> infection in a child with congenital ichthyosis. Pediatric Dermatology, 2018, 35, 259-260.	0.5	45
60	Detection of Polish clinical <i>Aspergillus fumigatus</i> isolates resistant to triazoles. Medical Mycology, 2018, 56, 121-124.	0.3	14
61	Treatment of candidemia in a nationwide setting: increased survival with primary echinocandin treatment. Infection and Drug Resistance, 2018, Volume 11, 2449-2459.	1.1	8
62	Implications of the EUCAST Trailing Phenomenon in <i>Candida tropicalis</i> for the In Vivo Susceptibility in Invertebrate and Murine Models. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	43
63	EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICs. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	49
64	Azole-Resistance in <i>Aspergillus terreus</i> and Related Species: An Emerging Problem or a Rare Phenomenon?. Frontiers in Microbiology, 2018, 9, 516.	1.5	66
65	Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial Cell, 2018, 5, 300-326.	1.4	81
66	Invasive candidiasis. Nature Reviews Disease Primers, 2018, 4, 18026.	18.1	841
67	APX001A In Vitro Activity against Contemporary Blood Isolates and <i>Candida auris</i> Determined by the EUCAST Reference Method. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	42
68	Polyphasic data support the splitting of <i>Aspergillus candidus</i> into two species; proposal of <i>Aspergillus dobrogensis</i> sp. nov.. International Journal of Systematic and Evolutionary Microbiology, 2018, 68, 995-1011.	0.8	21
69	Two Cases of Proximal Subungual Onychomycosis Caused by <i>Trichophyton rubrum</i> in HIV-negative Patients During Treatment with TNF- $\alpha$ Inhibitors Combined with Methotrexate. Acta Dermatovenerologica Croatica, 2018, 26, 304-306.	0.1	2
70	Successful Treatment of Rhino-Orbital-Cerebral Mucormycosis in a Child With Leukemia. Journal of Pediatric Hematology/Oncology, 2017, 39, e211-e215.	0.3	16
71	Implementation of Isavuconazole in a Fluorescence-Based High-Performance Liquid Chromatography Kit Allowing Simultaneous Detection of All Four Currently Licensed Mold-Active Triazoles. MSphere, 2017, 2, .	1.3	9
72	Multidrug-Resistant <i>Candida</i> : Epidemiology, Molecular Mechanisms, and Treatment. Journal of Infectious Diseases, 2017, 216, S445-S451.	1.9	450

#	ARTICLE	IF	CITATIONS
73	Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant <i>Aspergillus fumigatus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3325-3333.	1.3	39
74	Fluconazole Pharmacokinetics in <i>Galleria mellonella</i> Larvae and Performance Evaluation of a Bioassay Compared to Liquid Chromatography-Tandem Mass Spectrometry for Hemolymph Specimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	20
75	Molecular basis of antifungal drug resistance in yeasts. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 599-606.	1.1	72
76	Evaluation of MIC Strip Isavuconazole Test for Susceptibility Testing of Wild-Type and Non-Wild-Type <i>Aspergillus fumigatus</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	15
77	Differences in epidemiology of candidaemia in the Nordic countries – what is to blame?. <i>Mycoses</i> , 2017, 60, 11-19.	1.8	21
78	Darier Disease Complicated by Terbinafine-resistant <i>Trichophyton rubrum</i> : A Case Report. <i>Acta Dermato-Venereologica</i> , 2017, 97, 139-140.	0.6	51
79	Azole Resistance of <i>Aspergillus fumigatus</i> in Immunocompromised Patients with Invasive Aspergillosis. <i>Emerging Infectious Diseases</i> , 2016, 22, 158-159.	2.0	27
80	How to Optimize the Use of Blood Cultures for the Diagnosis of Bloodstream Infections? A State-of-the Art. <i>Frontiers in Microbiology</i> , 2016, 7, 697.	1.5	234
81	Molecular epidemiology and <i>in vitro</i> antifungal susceptibility testing of 108 clinical <i>Cryptococcus neoformans sensu lato</i> and <i>Cryptococcus gattii sensu lato</i> isolates from Denmark. <i>Mycoses</i> , 2016, 59, 576-584.	1.8	46
82	Invasive Candidiasis. <i>New England Journal of Medicine</i> , 2016, 374, 793-795.	13.9	47
83	<i>In Vitro</i> Activity of ASP2397 against <i>Aspergillus</i> Isolates with or without Acquired Azole Resistance Mechanisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 532-536.	1.4	32
84	The burden of fungal disease in Denmark. <i>Mycoses</i> , 2015, 58, 15-21.	1.8	19
85	<i>In Vitro</i> Activity of Isavuconazole and Comparators against Clinical Isolates of the <i>Mucorales</i> Order. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7735-7742.	1.4	89
86	First report of <i>Candida palmiophila</i> endogenous endophthalmitis. <i>Acta Ophthalmologica</i> , 2015, 93, e517-8.	0.6	7
87	Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance <i>in vivo</i> in <i>Candida albicans</i> orchestrated by multiple genetic alterations. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2551-2555.	1.3	64
88	Recurrent prosthetic valve endocarditis caused by <i>Aspergillus delacroixii</i> (formerly <i>Aspergillus</i> ) Tj ETQq0 0 0 rgBT /Oyerlock 10 Tf 50 142	0.7	
89	In vitro activity of 23 tea extractions and epigallocatechin gallate against <i>Candida</i> species. <i>Medical Mycology</i> , 2015, 53, 194-198.	0.3	32
90	Discovery of a sexual stage in <i>Trichophyton onychocola</i> , a presumed geophilic dermatophyte isolated from toenails of patients with a history of <i>T. rubrum</i> onychomycosis. <i>Medical Mycology</i> , 2015, 53, 798-809.	0.3	25

#	ARTICLE	IF	CITATIONS
91	The State-of-the-Art Mycology Laboratory: Visions of the Future. <i>Current Fungal Infection Reports</i> , 2015, 9, 37-51.	0.9	5
92	Invasive Candida Infections and the Harm From Antibacterial Drugs in Critically Ill Patients. <i>Critical Care Medicine</i> , 2015, 43, 594-602.	0.4	39
93	Invasive Candidiasis. <i>New England Journal of Medicine</i> , 2015, 373, 1445-1456.	13.9	962
94	International expert opinion on the management of infection caused by azole-resistant <i>Aspergillus fumigatus</i> . <i>Drug Resistance Updates</i> , 2015, 21-22, 30-40.	6.5	262
95	Echinocandin resistance. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 484-492.	1.3	259
96	EUCAST Testing of Isavuconazole Susceptibility in <i>Aspergillus</i> : Comparison of Results for Inoculum Standardization Using Conidium Counting versus Optical Density. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6432-6436.	1.4	12
97	Vertebral infection with <i>Candida albicans</i> failing caspofungin and fluconazole combination therapy but successfully treated with high dose liposomal amphotericin B and flucytosine. <i>Medical Mycology Case Reports</i> , 2014, 6, 6-9.	0.7	10
98	Echinocandin Failure Case Due to a Previously Unreported <i>FKS1</i> Mutation in <i>Candida krusei</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3550-3552.	1.4	26
99	EUCAST Technical Note on <i>Candida</i> and micafungin, anidulafungin and fluconazole. <i>Mycoses</i> , 2014, 57, 377-379.	1.8	38
100	Performance of matrix-assisted laser desorption-time of flight mass spectrometry for identification of clinical yeast isolates. <i>Mycoses</i> , 2013, 56, 229-235.	1.8	48
101	Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against <i>Candida</i> spp. and triazoles against <i>Aspergillus</i> spp.. <i>Drug Resistance Updates</i> , 2013, 16, 81-95.	6.5	106
102	Evaluation of Caspofungin Susceptibility Testing by the New Vitek 2 AST-YS06 Yeast Card Using a Unique Collection of <i>FKS</i> Wild-Type and Hot Spot Mutant Isolates, Including the Five Most Common <i>Candida</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 177-182.	1.4	41
103	Stepwise Development of a Homozygous S80P Substitution in Fks1p, Conferring Echinocandin Resistance in <i>Candida tropicalis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 614-617.	1.4	45
104	Determination of Isavuconazole Susceptibility of <i>Aspergillus</i> and <i>Candida</i> Species by the EUCAST Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5426-5431.	1.4	64
105	Azole resistance in <i>Aspergillus fumigatus</i> from bronchoalveolar lavage fluid samples of patients with chronic diseases. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1497-1504.	1.3	45
106	PCR test for <i>Microsporium canis</i> identification. <i>Medical Mycology</i> , 2013, 51, 576-579.	0.3	29
107	Composite Survival Index to Compare Virulence Changes in Azole-Resistant <i>Aspergillus fumigatus</i> Clinical Isolates. <i>PLoS ONE</i> , 2013, 8, e72280.	1.1	20
108	<i>Candida</i> and candidaemia. Susceptibility and epidemiology. <i>Danish Medical Journal</i> , 2013, 60, B4698.	0.5	98

#	ARTICLE	IF	CITATIONS
109	In Vivo Emergence of <i>Aspergillus terreus</i> with Reduced Azole Susceptibility and a Cyp51a M217I Alteration. <i>Journal of Infectious Diseases</i> , 2012, 206, 981-985.	1.9	55
110	Comparison of Dimethyl Sulfoxide and Water as Solvents for Echinocandin Susceptibility Testing by the EUCAST Methodology. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2509-2512.	1.8	19
111	Differential <i>In Vivo</i> Activities of Anidulafungin, Caspofungin, and Micafungin against <i>Candida glabrata</i> Isolates with and without FKS Resistance Mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2435-2442.	1.4	107
112	Caspofungin Etest Susceptibility Testing of <i>Candida</i> Species: Risk of Misclassification of Susceptible Isolates of <i>C. glabrata</i> and <i>C. krusei</i> when Adopting the Revised CLSI Caspofungin Breakpoints. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3965-3968.	1.4	61
113	Pharmacodynamics of Voriconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis: Implications for In Vitro Susceptibility Breakpoints. <i>Journal of Infectious Diseases</i> , 2012, 206, 442-452.	1.9	35
114	Molecular diagnosis of dermatophyte infections. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 126-134.	1.3	69
115	EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). <i>Clinical Microbiology and Infection</i> , 2012, 18, E246-E247.	2.8	368
116	Azole-Resistant Invasive Aspergillosis: Relationship to Agriculture. <i>Current Fungal Infection Reports</i> , 2012, 6, 178-191.	0.9	64
117	Discovery of a hapE Mutation That Causes Azole Resistance in <i>Aspergillus fumigatus</i> through Whole Genome Sequencing and Sexual Crossing. <i>PLoS ONE</i> , 2012, 7, e50034.	1.1	168
118	Acquired antifungal drug resistance in <i>Aspergillus fumigatus</i> : epidemiology and detection. <i>Medical Mycology</i> , 2011, 49, S90-S95.	0.3	172
119	Evaluation of CLSI M44-A2 Disk Diffusion and Associated Breakpoint Testing of Caspofungin and Micafungin Using a Well-Characterized Panel of Wild-Type and FKS Hot Spot Mutant <i>Candida</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1891-1895.	1.4	20
120	Clinical breakpoints for voriconazole and <i>Candida</i> spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 70, 330-343.	0.8	117
121	Successful management of invasive aspergillosis presenting as pericarditis in an adult patient with chronic granulomatous disease. <i>Mycoses</i> , 2011, 54, e233-e236.	1.8	17
122	Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?. <i>Current Fungal Infection Reports</i> , 2011, 5, 128-134.	0.9	5
123	<i>Candida palmioleophila</i> : Characterization of a Previously Overlooked Pathogen and Its Unique Susceptibility Profile in Comparison with Five Related Species. <i>Journal of Clinical Microbiology</i> , 2011, 49, 549-556.	1.8	60
124	Diagnostic Issues, Clinical Characteristics, and Outcomes for Patients with Fungemia. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3300-3308.	1.8	147
125	Echinocandin Susceptibility Testing of <i>Candida</i> spp. Using EUCAST EDef 7.1 and CLSI M27-A3 Standard Procedures: Analysis of the Influence of Bovine Serum Albumin Supplementation, Storage Time, and Drug Lots. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1580-1587.	1.4	53
126	Echinocandin Susceptibility Testing of <i>Candida</i> Isolates Collected during a 1-Year Period in Sweden. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2516-2521.	1.8	22



#	ARTICLE	IF	CITATIONS
127	Aspergillus Species and Other Molds in Respiratory Samples from Patients with Cystic Fibrosis: a Laboratory-Based Study with Focus on Aspergillus fumigatus Azole Resistance. Journal of Clinical Microbiology, 2011, 49, 2243-2251.	1.8	164
128	National Surveillance of Fungemia in Denmark (2004 to 2009). Journal of Clinical Microbiology, 2011, 49, 325-334.	1.8	206
129	Epidemiology of invasive candidiasis. Current Opinion in Critical Care, 2010, 16, 445-452.	1.6	326
130	Optimized 5-hour multiplex PCR test for the detection of tinea unguium: performance in a routine PCR laboratory. Medical Mycology, 2010, 48, 828-831.	0.3	55
131	Development of Azole Resistance in Aspergillus fumigatus during Azole Therapy Associated with Change in Virulence. PLoS ONE, 2010, 5, e10080.	1.1	143
132	Comparison of Caspofungin MICs by Means of EUCAST Method EDef 7.1 Using Two Different Concentrations of Glucose. Antimicrobial Agents and Chemotherapy, 2010, 54, 3056-3057.	1.4	5
133	Echinocandin Susceptibility Testing of <i>Candida</i> Species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media. Antimicrobial Agents and Chemotherapy, 2010, 54, 426-439.	1.4	144
134	Environmental Study of Azole-Resistant <i>Aspergillus fumigatus</i> and Other Aspergilli in Austria, Denmark, and Spain. Antimicrobial Agents and Chemotherapy, 2010, 54, 4545-4549.	1.4	217
135	Multicenter Comparison of the ISO Standard 20776-1 and the Serial 2-Fold Dilution Procedures To Dilute Hydrophilic and Hydrophobic Antifungal Agents for Susceptibility Testing. Journal of Clinical Microbiology, 2010, 48, 1918-1920.	1.8	6
136	Typing of Candida isolates from patients with invasive infection and concomitant colonization. Scandinavian Journal of Infectious Diseases, 2010, 42, 109-113.	1.5	30
137	Diagnostic PCR tests for <i>Microsporium audouinii</i> , <i>M. canis</i> and <i>Trichophyton</i> infections. Medical Mycology, 2010, 48, 486-490.	0.3	27
138	Molecular screening for Candida orthopsilosis and Candidametapsilosis among Danish Candida parapsilosis group blood culture isolates: proposal of a new RFLP profile for differentiation. Journal of Medical Microbiology, 2010, 59, 414-420.	0.7	60
139	EUCAST breakpoints for antifungals. Drug News and Perspectives, 2010, 23, 93.	1.9	40
140	Frequency and Evolution of Azole Resistance in <i>Aspergillus fumigatus</i> Associated with Treatment Failure. Emerging Infectious Diseases, 2009, 15, 1068-1076.	2.0	692
141	Breakthrough <i>Aspergillus fumigatus</i> and <i>Candida albicans</i> Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing. Antimicrobial Agents and Chemotherapy, 2009, 53, 1185-1193.	1.4	110
142	Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia. Antimicrobial Agents and Chemotherapy, 2009, 53, 2704-2706.	1.4	9
143	Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species. Antimicrobial Agents and Chemotherapy, 2009, 53, 1628-1629.	1.4	52
144	Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Medicine, 2009, 35, 55-62.	3.9	148

#	ARTICLE	IF	CITATIONS
145	Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment. <i>Intensive Care Medicine</i> , 2009, 35, 206-214.	3.9	75
146	Establishing In Vitro-In Vivo Correlations for <i>Aspergillus fumigatus</i> : the Challenge of Azoles versus Echinocandins. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3504-3511.	1.4	98
147	Rapid and Accurate Identification of <i>Candida albicans</i> Isolates by Use of PNA FISH <sup>Flow</sup> . <i>Journal of Clinical Microbiology</i> , 2008, 46, 1537-1540.	1.8	29
148	Laboratory-based Survey of Dermatophyte Infections in Denmark over a 10-year Period. <i>Acta Dermato-Venereologica</i> , 2008, 88, 614-616.	0.6	33
149	Does One Voriconazole Breakpoint Suit All <i>Candida</i> Species?. <i>Journal of Clinical Microbiology</i> , 2007, 45, 2093-2094.	1.8	6
150	Detecting <i>Blastocystis</i> using parasitologic and DNA-based methods: a comparative study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 59, 303-307.	0.8	159
151	Diagnostics of fungal infections in the Nordic countries: We still need to improve!. <i>Scandinavian Journal of Infectious Diseases</i> , 2007, 39, 337-343.	1.5	16
152	Five-Hour Diagnosis of Dermatophyte Nail Infections with Specific Detection of <i>Trichophyton rubrum</i> . <i>Journal of Clinical Microbiology</i> , 2007, 45, 1200-1204.	1.8	129
153	DETECTION OF <i>BLASTOCYSTIS HOMINIS</i> IN UNPRESERVED STOOL SPECIMENS BY USING POLYMERASE CHAIN REACTION. <i>Journal of Parasitology</i> , 2006, 92, 1081-1087.	0.3	107
154	Amphotericin B and Caspofungin Resistance in <i>Candida glabrata</i> Isolates Recovered from a Critically Ill Patient. <i>Clinical Infectious Diseases</i> , 2006, 42, 938-944.	2.9	184
155	Acute pulmonary aspergillosis in immunocompetent subjects after exposure to bark chippings. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 945-949.	1.5	25
156	Seminal Surveillance of Fungemia in Denmark: Notably High Rates of Fungemia and Numbers of Isolates with Reduced Azole Susceptibility. <i>Journal of Clinical Microbiology</i> , 2005, 43, 4434-4440.	1.8	147
157	Isolation of HIV from cultures of purified CD4+ lymphocytes. <i>Journal of Virological Methods</i> , 1991, 35, 15-25.	1.0	14